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Abstract
Background: Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for use in
patients with acute ischaemic stroke who meet strictly defined criteria. IST-3 sought to improve the external
validity and precision of the estimates of the overall treatment effects (efficacy and safety) of rtPA in acute
ischaemic stroke, and to determine whether a wider range of patients might benefit.
Design: International, multi-centre, prospective, randomized, open, blinded endpoint (PROBE) trial of intravenous
rtPA in acute ischaemic stroke. Suitable patients had to be assessed and able to start treatment within 6 hours of
developing symptoms, and brain imaging must have excluded intracranial haemorrhage and stroke mimics.
Results: The initial pilot phase was double blind and then, on 01/08/2003, changed to an open design.
Recruitment began on 05/05/2000 and closed on 31/07/2011, by which time 3035 patients had been included,
only 61 (2%) of whom met the criteria for the 2003 European approval for thrombolysis. 1617 patients were aged
over 80 years at trial entry. The analysis plan will be finalised, without reference to the unblinded data, and
published before the trial data are unblinded in early 2012. The main trial results will be presented at the European
Stroke Conference in Lisbon in May 2012 with the aim to publish simultaneously in a peer-reviewed journal. The
trial result will be presented in the context of an updated Cochrane systematic review. We also intend to include
the trial data in an individual patient data meta-analysis of all the relevant randomised trials.
Conclusion: The data from the trial will: improve the external validity and precision of the estimates of the overall
treatment effects (efficacy and safety) of iv rtPA in acute ischaemic stroke; provide: new evidence on the balance of
risk and benefit of intravenous rtPA among types of patients who do not clearly meet the terms of the current EU
approval; and, provide the first large-scale randomised evidence on effects in patients over 80, an age group which
had largely been excluded from previous acute stroke trials.
Trial registration: ISRCTN25765518
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Progress with the study and modifications to the
design
Planning for the third international stroke trial (IST-3)
of thrombolysis for acute ischaemic stroke with intrave-
nous recombinant tissue plasminogen activator (rtPA)
began in 1998. At its outset in 2000, the trial was
planned as a pragmatic trial which sought to improve
the external validity and precision of the estimates of
the overall treatment effects (efficacy and safety) of rtPA
in acute ischaemic stroke and to determine whether a
wider variety of patients than previously thought might
benefit from this treatment. After the drug was
approved for use in Europe in 2003, the flexible trial
eligibility criteria enabled us to continue recruiting
patients who did not clearly meet all the criteria set out
in the provisional European licence for the drug. With
these changes and the need to comply with the increas-
ingly burdensome requirements of research regulation
in Europe, some aspects of the trial protocol and its
practical procedures have inevitably had to change over
the 12 year course of the study. The initial pilot phase
of the study, funded by the UK Stroke Association, had
a double-blind design, for which Boehringer Ingelheim
provided a supply of drug and matching placebo. How-
ever, Boehringer Ingelheim did not wish to provide
further drug supplies for the expansion phase, funded
by The UK Health Foundation, and hence the design of
this phase of the study was modified. With appropriate
ethical approval, the expansion phase was designed as a
prospective, randomised, open blinded endpoint
(PROBE) trial and the first patient was recruited in this
phase on 1st August 2003. The main phase of the trial
was awarded funding by the UK Medical Research
Council and began on 1st April 2005. The protocol for
the MRC phase of the trial was published in Trials[1]..
At each stage, relevant amendments were made to the
protocol, and consolidated in an updated protocol (ver-
sion 1.93) which was approved by appropriate authori-
ties and published on the trial website http://www.ist3.
com (additional data file 1). When advanced imaging
techniques became more widely available in the partici-
pating centres, the study group developed a nested ima-
ging study evaluating the role of CT and MR perfusion
and angiography (CTP/CTA/MRP/MRA) in patients
with acute ischaemic stroke. The cost-effectiveness of
thrombolysis is being investigated in a sub-study in the
Scandinavian region cohort.
Sample size/recruitment target
In our 2004 application to the MRC for funding of the
main phase of the trial we stated: ’Assuming the same
event rate as observed in the feasibility phases, the trial
could very reliably detect an absolute difference of 10%
in the proportion of patients dead or dependent at 6
months after treatment. With a sample size of 6000
patients, the trial would have > 99.9% power to detect
such a difference (alpha = 0.001) and sufficient power to
permit reliable analyses of the pre-specified subgroups. A
trial of this size could detect a smaller, but still clinically
worthwhile net benefit of as little as a 3% absolute dif-
ference in the primary outcome (80% power, at alpha =
0.05).’ The application to the MRC for funding was suc-
cessful, but by the time the grant was activated, two
major changes to research regulation came into force:
the European Clinical Trials Directive, the UK Clinical
Trials Regulations 2004, and, shortly afterwards, the UK
Research Governance Framework. These changes led to
a large increase in the time taken to recruit and activate
new centres and hence significantly reduced the rate of
increase in patient recruitment. By 2007, it was clear
that the various factors that had delayed recruitment
meant that the original target of 6000 was no longer fea-
sible, and we applied for approval to amend the recruit-
ment target and for additional funding to extend the
period of recruitment to mid 2011. These changes were
summarised in version 1.93 of the protocol (additional
document 1) as follows: “If 3500 patients were recruited,
the trial could detect a 4% absolute difference in the pri-
mary outcome. A sample size of 1000 patients could
detect a 7% absolute difference in the primary outcome,
which is consistent with the effect size among patients
randomised within 3 hours of stroke in the Cochrane
review. Amendment in the light of recruitment by
2007:. The Medical Research Council... awarded an
extension to funding to permit recruitment to continue
until mid 2011, with a revised recruitment target of 3100
which would yield 80% power to detect an absolute dif-
ference of 4.7% in the primary outcome.’
Recruitment
The pilot (double blind) phase of the trial began when
the first patient was randomised on 5th May 2000; six-
teen centres enrolled patients. Recruitment continued
without interruption into the open expansion phase
(first patient in this phase was randomised on 1st August
2003). In April 2005, recruitment continued with the
start of the MRC funded main phase. The independent
Data Monitoring Committee (DMC) met regularly
throughout the trial, in strict confidence, to review the
accumulating trial data and any other relevant external
data. Their terms of reference were set out in the proto-
col, and in the light of the evidence available, the DMC
did not recommend any change to the protocol or to
recruitment into the study. The trial closed to recruit-
ment on 31st July 2011, with a total of 3035 patients
from 156 hospitals in 12 countries (Table 1).
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Eligibility
The eligibility criteria are set out in full in the protocol,
but can be summarised in terms of the ‘uncertainty
principle’[2-4]. As this was a pragmatic trial, conducted
in the ‘;real world’[5], in order to ensure a wide variety
of patients were included, inclusion and exclusion cri-
teria were kept simple [6]. Patients were eligible if: they
had symptoms and signs of clinically definite acute
stroke; the time of stroke onset was known; treatment
could be started within six hours of this onset; and, CT
or MRI brain scanning had reliably excluded both intra-
cranial haemorrhage and structural brain lesions which
could mimic stroke (e.g cerebral tumour). In addition, if
the patient had a clear indication for intravenous throm-
bolysis with rtPA, they were to be treated in accordance
with local guidelines. Equally, if the patient had a clear
contraindication to treatment they were not to be
entered in the trial. Only if both the clinician and the
patient (or a relevant proxy for the patient) felt that the
treatment was ‘promising but unproven’, could the
patient be included in the trial after appropriate
informed consent. In order to comply with local regula-
tory and ethical requirements, the form of the consent
procedure applied varied somewhat between countries
and between centres within each country. Details of the
type of consent process applied will be reported
separately.
Baseline data collection and method of treatment
allocation
After informed consent had been obtained, the clinician
used either a voice-activated telephone or a secure web-
based randomisation system to enter a patient in the
study. The systems recorded and checked the baseline
characteristics of the patients and allocated the treat-
ment only after all baseline data had been entered and
passed range and consistency checks. We used a mini-
misation program to achieve optimum balance for key
prognostic factors (see Table 2a), and from January
2006, the minimisation algorithm was additionally strati-
fied by world region and minimised on everything else
within world region. Because simple minimisation
within centres can lead to alternation of treatment allo-
cation and thus potential loss of allocation concealment,
our system also incorporated a degree of random alloca-
tion. Patients were allocated to the treatment group that
would minimise the difference between the groups with
a probability of 0.80. For 244 patients in the initial
phase of the trial, the National Institutes of Health
Stroke Score (NIHSS) was not measured directly, but
was retrospectively estimated by an algorithm (derived
from subsequent patients in the trial based on baseline
clinical characteristics). In the initial double-blind phase,
the clinician was informed of the treatment allocation in
the form of a treatment pack number (which might con-
tain active drug or matching placebo). In the open
phase, the investigator was informed of the patient’s
treatment allocation (either thrombolysis with 0.9 mg/kg
i.v. rtPA or control). In both phases, the randomisation
system informed the local clinician of the dose (of drug
or placebo in the double blind phase, or of the drug
dose amongst those allocated thrombolysis in the open
phase) to be given as a bolus and as infusion, and the
patient’s unique trial ID number.
Baseline characteristics of patients
The characteristics of the patients recorded at baseline
are shown, for both treatment groups combined, in
Tables 2a and 3 (2b). Patients recruited within 1-2 hours
of onset were statistically significantly (p < 0.0001) more
likely to have a more severe neurological deficit than
those recruited at later time points after onset (Figure 1).
Similarly, patients recruited at earlier time points were
statistically significantly older than those recruited later
(p < 0.0001) (Figure 2). Additionally, the proportion of
patients with a visible ischaemic lesion on the baseline
imaging rose with time (data not shown).
Baseline characteristics of the patients in the
context of the prevailing evidence
The baseline characteristics of the patients recruited
into the study changed over the course of the study as
clinician’s uncertainties about which types of patients
should be treated changed. These changes arose from
appreciation of the accumulating evidence from rando-
mised controlled trials and consequent changes in the
European Licence and clinical guidelines. At the start of
the trial in 2000, rtPA was approved for use in the USA
and Canada, but was not approved for use in Europe.
In 2003, the European Medicines Agency granted
Table 1 Recruitment: number of centres and patients in
each country
No. of centres No. of patients %
UK 75 1447 47.7%
Poland 9 347 11.4%
Italy 21 326 10.7%
Sweden 18 297 9.8%
Norway 11 204 6.7%
Australia 10 179 5.9%
Portugal 4 82 2.7%
Belgium 1 73 2.4%
Austria 3 46 1.5%
Switzerland 2 23 0.8%
Canada 1 8 0.3%
Mexico 1 3 0.1%
Total 156 3035 100%
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provisional approval for the use of rtPA for patients
aged less than 80 years who could be treated within
three hours (and who also met a number of other cri-
teria). In 2008, when the ECASS-3 study reported evi-
dence of benefit for treatment between 3-4.5 hours [7],
guidelines in various European countries suggested that
patients aged less than 80 years could benefit even if
treated within 3-4.5 hours. We estimated the number of
patients in the trial that would have met either the origi-
nal 2003 approval criteria or the anticipated new 2011
criteria (modified in the light of the ECASS-3 data). If
we defined ‘meeting the 2003 approval’ as: age < 80,
delay from onset to randomisation < 3 hoyrs, NIHSS 6 -
25, SBP < = 185, DBP < = 110, 2.7 < = glucose < = 22
and no history of the combination of prior stroke and
diabetes mellitus, 61 patients (2%) met the criteria, and
if all the same criteria were applied and the time win-
dow was extended to 4.5 hours, 350 (12.7%) met the cri-
teria. This clearly demonstrates that the great majority
of the patients in IST-3 fall outside the European
approval criteria for rtPA., and hence the study will pro-
vide valuable new randomised information in many
categories of patient - as well the elderly - who are cur-
rently not eligible for treatment.
Development of the statistical analysis plan
The statistical analysis plan is being finalised at present,
without reference to the unblinded data, and will be
Table 2a Clinical characteristics at randomisation used in the minimisation algorithm
No. (%)
Region1 NW Europe (UK, Austria, Belgium, Switzerland) 1589 (52%)
Scandinavia (Norway, Sweden) 501 (17%)
Australasia 179 (6%)
Southern Europe (Italy, Portugal) 408 (13%)
Eastern Europe (Poland) 347 (11%)
Americas (Canada, Mexico) 11 (0%)
Sex Female 1570 (52%)
Male 1465 (48%)
Age < = 70 years 697 (23%)
> 70 years 2338 (77%)
Age (more detail) 18-50 127 (4%)
51-60 203 (7%)
61-70 367 (12%)
71-80 721 (24%)
81-90 1407 (46%)
over 90 210 (7%)
NIHSS2 0 to 5 612 (20%)
6 to 10 852 (28%)
11 to 15 601 (20%)
16 to 20 542 (18%)
21 to 35 428 (14%)
Stroke syndrome Other 2703 (89%)
Lacunar 332 (11%)
Delay in randomisation 0-3 hours 849 (28%)
> 3 hours 2186 (72%)
Delay (more detail) 0-3 hours 849 (28%)
3-4.5 hours 1178 (39%)
4.5-6 hours 1007 (33%)
> 6 hours3 1 (0%)
Antiplatelet agents < = 48 hours before randomisation Yes 1565 (52%)
No 1470 (48%)
1. From January 2006, the randomisation procedure has been stratified by world region and minimises on prognostic factors within world region, using a
random element.
2. For 244 patients in initial phase of the trial, NIHSS was not measured directly, but it was subsequently approximated using an algorithm (derived from
subsequent patients in the trial based on clinical characteristics that were measured at baseline).
3. Protocol violation
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published before the code is broken in early 2012. It will
take account of external evidence on factors influencing
prognosis and response to treatment, the baseline char-
acteristics of patients entering the study and advances in
statistical methodology [8,9]. The SAP will define a
small number of ‘primary’ subgroup analyses, and a
larger number of exploratory secondary analyses [8].
During the course of the trial, a number of novel
approaches to the analysis of ordered functional out-
come data in clinical trials of stroke treatment have
been suggested to improve statistical power Statistical
tests, which make use of the ordered nature of outcome
data, such as ordinal logistic regression and ‘shift analy-
sis’, may give more reliable results [9]. However, the
technique is not universally applicable and it is impor-
tant that key underlying assumptions are met for the
analyses to be valid [10]. The Trial Steering Committee
sought statistical advice, and because the underlying
assumptions would not necessarily be met in the IST3
dataset, decided an ordinal analysis was not appropriate
for the primary analysis of outcome. This decision was
also consistent with all the previous trials of intravenous
rtPA, none of which had adopted an ordinal approach
for the primary analysis. However, an ordinal analysis
has been included as one of the secondary exploratory
analyses. The trends in Figures 1 &2 demonstrate that
the statistical analysis plan will also need to take
account of these potentially confounding effects on
the assessment of treatment effects overall and in
subgroups.
Reporting of results by allocated treatment
The trial will be unblinded in early 2012 and the main
trial results presented at the European Stroke Confer-
ence in Lisbon in May 2012 with the aim of publishing
simultaneously in a peer-reviewed journal. The trial pri-
mary results will be presented in the context of an
updated Cochrane systematic review of all the relevant
randomised trials. The imaging sub-study CTP/CTA/
MRP/MRA results are due in early 2013. An individual
patient data meta-analysis of all trials testing intrave-
nous rtPA, including IST-3, is also being considered.
Table 2b Clinical characteristics at randomisation not used in minimisation algorithm, and recorded at randomisation
No. (%)
Cardiac rhythm Sinus rhythm, not AF 2121 (70%)
Atrial fibrillation 914 (30%)
Systolic BP at randomisation < = 140 mmHg 897 (30%)
141 to 180 mmHg 1738 (57%)
> 180 mmHg 400 (13%)
median (interquartile range) 155 (140, 170)
Diastolic BP at randomisation < = 80 mmHg 1537 (51%)
81 to 110 mmHg 1420 (47%)
> 110 mmHg 78 (3%)
median (interquartile range) 80 (71, 91)
Blood glucose1 < 3.5 mmol/l 7 (0%)
3.5-6 mmol/l 532 (18%)
6-8 mmol/l 1654 (54%)
> 8 mmol/l 559 (18%)
not measured (old form) 283 (9%)
median (interquartile range) 7.0 (6.0, 8.0)
Probability of being alive and independent at 6 m2 < 0.30 1383 (46%)
> = 0.30 1652 (54%)
median (interquartile range) 0.35 (0.12, 0.59)
Recruited at a centre with pre-trial experience3 Centres without pre-trial experience 1891 (62%)
Centre with pre-trial experience 1144 (38%)
Doctor’s opinion of scan at randomisation Normal 1792 (59%)
Possible evidence of recent ischaemic change 701 (23%)
Definite evidence of recent ischaemic change 542 (18%)
1. For the first 282 patients, glucose was not recorded. After patient 282, it was collected at randomisation. Glucose therefore was not available for those 282
patients
2. Probability calculated with a validated prognostic model from baseline data [14].
3. Pre-trial experience of thrombolysis is defined as having had a protocol for open label rtPA and had treated at least 3 people in the 12 months before joining
the trial; 76 (49%) centres met this criterion.
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Figure 1 Baseline stroke severity as assessed by NIHSS among patients randomised at different times after stroke onset. Plot displays
median and interquartile range. p value for linear regression on exact time since onset p < 0.0001.
Figure 2 Age among patients randomised at different times after stroke onset. Plot displays median and interquartile range. p value for
linear regression on exact time since onset p < 0.0001.
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Discussion
With 3035 patients, IST-3 is the largest ever randomised
trial of intravenous thrombolysis for the treatment of
acute ischaemic stroke (the two largest previous trials
each recruited exactly 800 patients [7,11]. At its outset
in 2000, the trial sought to improve the external validity
and precision of the estimates of the overall treatment
effects (efficacy and safety) of rtPA in acute ischaemic
stroke and to determine whether a wider variety of
patients than previously thought might benefit from this
treatment. With the approval of the treatment for speci-
fic types of patients, the trial was able to evaluate the
effects of treatment in patients who did not precisely
meet the existing European approval for the treatment;
in other words, also sought to extend the criteria for
treatment. At the start of the trial, when rtPA had not
yet received approval from the European regulatory
authorities, patients of all ages were recruited within 3
hours. After the provisional approval for the use of rtPA
in Europe in 2003 for those patients aged less than 80
years who could be treated within three hours, partici-
pating clinicians generally opted to treat patients who
met the conditions of the licence, and hence only
recruited only those patients in IST3 that did not strictly
meet the licence criteria. The elderly have been under-
represented in trials of treatments for acute stroke [12],
especially thrombolysis with rtPA, where fewer than 100
patients aged over 80 years have been included in ran-
domised trials of this treatment [13]. IST-3 has included
1617 patients aged over 80, so will provide valuable ran-
domised evidence on the balance of risk and benefit in
this much under-researched, but increasingly important
age-group [12]. IST3 has shown that pragmatic trial
designs with broad and flexible entry criteria can recruit
large numbers of patients, even in the face of changing
and burdensome regulatory regimes; the emergence of
new data from other relevant trials and rapidly changing
clinical practice.
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